126 related articles for article (PubMed ID: 8857552)
1. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
3. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients.
Turgeon DK; Leichtman AB; Lown KS; Normolle DP; Deeb GM; Merion RM; Watkins PB
Clin Pharmacol Ther; 1994 Sep; 56(3):253-60. PubMed ID: 7924120
[TBL] [Abstract][Full Text] [Related]
4. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
Watkins PB; Turgeon DK; Saenger P; Lown KS; Kolars JC; Hamilton T; Fishman K; Guzelian PS; Voorhees JJ
Clin Pharmacol Ther; 1992 Sep; 52(3):265-73. PubMed ID: 1526083
[TBL] [Abstract][Full Text] [Related]
5. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients.
Turgeon DK; Normolle DP; Leichtman AB; Annesley TM; Smith DE; Watkins PB
Clin Pharmacol Ther; 1992 Nov; 52(5):471-8. PubMed ID: 1424421
[TBL] [Abstract][Full Text] [Related]
6. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
7. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
9. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
[TBL] [Abstract][Full Text] [Related]
10. Effects of metronidazole on hepatic CYP3A4 activity.
Haas CE; Kaufman DC; DiCenzo RC
Pharmacotherapy; 2001 Oct; 21(10):1192-5. PubMed ID: 11601665
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4 and the erythromycin breath test.
Wagner D
Clin Pharmacol Ther; 1998 Jul; 64(1):129-30. PubMed ID: 9695728
[No Abstract] [Full Text] [Related]
12. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
13. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
[TBL] [Abstract][Full Text] [Related]
14. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test.
Tateishi T; Graham SG; Krivoruk Y; Wood AJ
Br J Clin Pharmacol; 1995 Oct; 40(4):411-2. PubMed ID: 8554946
[No Abstract] [Full Text] [Related]
16. Effect of influenza immunization on CYP3A4 activity.
Hayney MS; Hammes RJ; Fine JP; Bianco JA
Vaccine; 2001 Dec; 20(5-6):858-61. PubMed ID: 11738750
[TBL] [Abstract][Full Text] [Related]
17. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.
Gharaibeh MN; Gillen LP; Osborne B; Schwartz JI; Waldman SA
J Clin Pharmacol; 1998 Jun; 38(6):492-5. PubMed ID: 9650537
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
19. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease.
Lown K; Kolars J; Turgeon K; Merion R; Wrighton SA; Watkins PB
Clin Pharmacol Ther; 1992 Mar; 51(3):229-38. PubMed ID: 1544283
[TBL] [Abstract][Full Text] [Related]
20. Variability in activity of hepatic CYP3A4 in patients infected with HIV.
Slain D; Pakyz A; Israel DS; Monroe S; Polk RE
Pharmacotherapy; 2000 Aug; 20(8):898-907. PubMed ID: 10939550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
